Novo Nordisk Plunges Nearly 15% After Earnings. Here's What Investors Need to Know.

Novo Nordisk is expecting earnings to decline in 2026. The company's GLP-1 pill has seen more demand than management expected.

The Motley Fool • 3 hours ago

Weight-loss drugs to compete on biggest stage with Super Bowl ads

Companies looking to sell weight-loss drugs directly to consumers, including Novo Nordisk's Wegovy, will shell out millions of dollars for celebrity-filled ads during Sunday's Super Bowl with its promise of one of the year's largest global audiences.

Reuters • Feb 7, 2026

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.

Eli Lilly's stock price rose sharply as demand for its GLP-1 drugs increased. Novo Nordisk is the second fiddle in GLP-1 drugs, but its GLP-1 pill is seeing strong demand.

The Motley Fool • 21 hours ago

Heard on the Street: : The obesity-market price war has turned traditional pharma economics upside down.

Prices for GLP-1s are falling fast, forcing companies to adapt.

WSJ • Feb 7, 2026

Novo Nordisk shares rebound as FDA targets illegal drug copies

Shares in Danish drugmaker Novo Nordisk gained 4.7% in early trading on Friday, recovering some of the previous two sessions' steep losses, after the U.S. Food and Drug Administration (FDA) pledged to address mass-marketing of unapproved drugs.

Reuters • Feb 6, 2026

Citi flags lingering risks to Novo despite strong weight-loss portfolio

Citi has warned that Novo Nordisk (NYSE:NVO) inability to curb the use of compounded semaglutide may weigh on investor sentiment, despite the strength of its obesity drug portfolio. In a note following Novo's post-results meeting in London, analysts said the launch of a compounded semaglutide pill by Hims & Hers, priced at $49 to $99, posed a challenge to the company's Wegovy pill, which starts at $149.

Proactive Investors • Feb 6, 2026

Why Shares of Novo Nordisk Stock Collapsed This Week

Novo Nordisk reported sales growth for 2025, but is guiding for sales and earnings declines in 2026. The company is facing major pricing pressure from the US government, as well as competition in weight-loss drugs.

The Motley Fool • Feb 6, 2026

Generic Ozempic Will Upend the Global Weight-Loss Drug Market

Novo Nordisk is predicting a 13% drop in sales in 2026. As the company's patents on Ozempic expire, could cheaper, generic versions give the company a run for its money?

Bloomberg Markets and Finance • Feb 6, 2026

Why Novo Nordisk stock fell 7% after a telehealth startup's announcement

Novo Nordisk's stock dove 7% on Thursday just after an announcement from a key competitor.

Fast Company • Feb 6, 2026

What's Going On With Novo Nordisk Stock On Friday?

Novo Nordisk A/S (NYSE: NVO) is trading higher on Friday after falling for two consecutive days on lower-than-expected fiscal 2026 guidance and compounding concerns.

Benzinga • Feb 6, 2026